These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 23467955

  • 1. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M, Nordio M, Pajalich R.
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M.
    J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
    [Abstract] [Full Text] [Related]

  • 8. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
    Minozzi M, Costantino D, Guaraldi C, Unfer V.
    Gynecol Endocrinol; 2011 Nov; 27(11):920-4. PubMed ID: 21417594
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML, Soulage CO.
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
    Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V.
    Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
    [Abstract] [Full Text] [Related]

  • 14. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
    Gateva A, Unfer V, Kamenov Z.
    Gynecol Endocrinol; 2018 Jul; 34(7):545-550. PubMed ID: 29309199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V, Di Sabatino A, Musacchio MC, De Leo V.
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [Abstract] [Full Text] [Related]

  • 17. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A.
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [Abstract] [Full Text] [Related]

  • 20. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
    Wan DH, Fan P, Bai H, Song Q, Liu HW.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.